Q8TCD0 (Q8TCD0_HUMAN) Homo sapiens (Human)
Ig-like domain-containing protein UniProtKBInterProInteractive Modelling
239 aa; Sequence (Fasta)
It is possible new templates exist for this target since these models were created.
Available Structures
38 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Crystal structure of APE1551, an anti-human NGF Fab with a nine amino acid insertion in CDR H1 |
Heteromer P01857; | |||||
| Assess | ||||||
| RSV-neutralizing human antibody AM22 |
Heteromer Q6GMX6; | 17×EDO; | ||||
| Assess | ||||||
| Crystal structure of the anti-human NGF Fab APE1531 |
Heteromer P01857; | 2×MES; 4×ACT; 1×PGE; | ||||
| Assess | ||||||
| Crystal structure of Fab fragment of anti-CD22 Epratuzumab |
Heteromer Q6N089; | |||||
| Assess | ||||||
| Crystal structure of maltose bound MBP with a conformationally specific synthetic antigen binder (s… |
Heteromer P0AEX9; P0DOX5; | 1×GLC; 2×IMD; 2×GOL; | ||||
| Assess | ||||||
| Structure of Bevacizumab Fab mutant in complex with VEGF |
Heteromer P0DOX5; P15692; | 2×SO4; 2×MES; | ||||
| Assess | ||||||
| Clostridium difficile TcdB-GTD bound to PA41 Fab |
Heteromer S6B291; | |||||
| Assess | ||||||
| Crystal structure of broadly neutralizing Influenza A antibody 429 B01 in complex with Hemagglutini… |
Heteromer A8K008; Q91MA7; | 6×NAG; | ||||
| Assess | ||||||
| RSV prefusion F in complex with AM22 Fab |
Heteromer P03420; Q6GMX6; | 3×NAG; 3×CD; 6×PEG; | ||||
| Assess | ||||||
| Crystal structure of RSV F bound by AM22 and the infant antibody ADI-19425 |
Heteromer A0A0B4J1V1; P03420; P0DOX5; Q6GMX4; Q6GMX6; | |||||
| Assess | ||||||
| Crystal structure of HCMV Pentamer in complex with neutralizing antibody 9I6 |
Heteromer F5HCP3; F5HET4; P16837; Q68674; Q6SW67; S6B291; | 3×NAG; 2×NAG; 1×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P2B-1A10 |
Heteromer A0A5C2GF00; P01594; P0DOX5; P0DTC2; | 21×NAG; 28×NAG; | ||||
| Assess | ||||||
| Structure of a mutant Cetuximab Fab fragment |
Heteromer P0DOX5; | 3×SO4; 5×GOL; | ||||
| Assess | ||||||
| Fab397 in complex with NPNA peptide |
Heteromer A8K008; P02893; | |||||
| Assess | ||||||
| Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment with a gp41 MPER-derived … |
Heteromer P04578; S6B291; | 1×NA; | ||||
| Assess | ||||||
| Crystal structure of HIV-1 broadly neutralizing antibody PGT152 |
Heteromer Q6N089; | |||||
| Assess | ||||||
| Crystal structure of HIV-1 broadly neutralizing antibody PGT151 |
Heteromer S6BAM6; | 2×P6G; | ||||
| Assess | ||||||
| Inhibiting Alternative Pathway Complement Activation by Targeting the Exosite on Factor D |
Heteromer F6YBP7; P01857; | 3×GOL; 4×ZN; 2×SO4; | ||||
| Assess | ||||||
| Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment |
Heteromer Q6N089; | 4×SO4; 3×EDO; 1×CL; | ||||
| Assess | ||||||
| Crystal structure of catalytic elimination antibody 34E4, triclinic crystal form |
Heteromer Q6N089; | 3×CD; | ||||
| Assess | ||||||
| Crystal structure of catalytic elimination antibody 34E4, orthorhombic crystal form |
Heteromer Q6N089; | 1×GOL; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of human monoclonal antibody H3v-47 |
Heteromer Q6N089; | |||||
| Assess | ||||||
| Structure of Hepatitis C Virus Envelope Glycoprotein E2 core from genotype 6a bound to broadly neut… |
Heteromer B9V0E2; P0DOX5; | 4×NAG; | ||||
| Assess | ||||||
| BG505 SOSIP.664 in complex with broadly neutralizing antibodies PG9 and 8ANC195 |
Heteromer P0DOX5; Q2N0S6; Q6GMW3; S6B291; | |||||
| Assess | ||||||
| BG505 SOSIP.664 in complex with broadly neutralizing antibodies BG1 and 8ANC195 |
Heteromer P01834; Q2N0S6; S6B291; | 10×NAG; 18×NAG; 5×NAG; 3×NAG; 7×NAG; 1×NAG; 13×NAG; | ||||
| Assess | ||||||
| Human antibody S5V2-29 in complex with influenza hemagglutinin A/Texas/50/2012 (H3N2) |
Heteromer R4L1D1; | 1×NAG; 1×NAG; 1×NAG; 1×NAG; 4×GOL; | ||||
| Assess | ||||||
| Crystal structure of the SF12 Fab |
Heteromer P0DOX5; | |||||
| Assess | ||||||
| Crystal structure of human monoclonal antibody H3v-47 in complex with influenza virus hemagglutinin… |
Heteromer I0AXC3; Q6N089; | 6×NAG; 3×NAG; 3×NAG; 3×NAG; 3×NAG; 6×NAG; 3×ZN; | ||||
| Assess | ||||||
| Crystal structure of the non-neutralizing HIV antibody 13H11 Fab fragment with a gp41 MPER-derived … |
Heteromer P04578; S6B291; | 1×EDO; | ||||
| Assess | ||||||
| Structure of Cetuximab Fab mutant in complex with EGFR extracellular domain |
Heteromer P00533; P0DOX5; | 1×NAG; 1×NAG; 3×NAG; | ||||
| Assess | ||||||
| CD22 d1-d3 in complex with therapeutic Fab Epratuzumab |
Heteromer P20273; S6B291; | 1×NAG; 1×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P5A-1B6_3B |
Heteromer P01594; P0DOX5; P0DP02; P0DTC2; | 20×NAG; 31×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P5A-1B6_2B |
Heteromer P01594; P0DOX5; P0DP02; P0DTC2; | 21×NAG; 28×NAG; | ||||
| Assess | ||||||
| Ectodomain of full length, wild type HIV-1 glycoprotein clone PC64M18C043 in complex with PGT151 Fab |
Heteromer A0A2H4K974; S6B291; | 1×NAG; 26×NAG; 1×NAG; 1×NAG; 1×NAG; 1×NAG; 2×NAG; 1×NAG; 1×NAG; 21×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P5A-1B8_2B |
Heteromer A0A5C2GCZ2; A0A5C2GG81; P0DTC2; Q6GMX6; | 20×NAG; 30×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P5A-1B8_3B |
Heteromer A0A5C2GCZ2; A0A5C2GG81; P0DTC2; Q6GMX6; | 20×NAG; 31×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with FabP5A-1B8 |
Heteromer A0A5C2GCZ2; A0A5C2GF00; P0DTC2; Q6GMX6; | 21×NAG; 28×NAG; | ||||
| Assess | ||||||
| S protein of SARS-CoV-2 in complex bound with P5A-1B9 |
Heteromer A0A5C2G1U0; P01825; P0DTC2; Q6GMX6; | 19×NAG; 33×NAG; | ||||
| Assess | ||||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 6mlk.1.B | monomer | 0.85 | 86.96 | |||
| Assess | ||||||